J Cancer 2016; 7(8):1002-1009. doi:10.7150/jca.14645
Glypican-1 as a Biomarker for Prostate Cancer: Isolation and Characterization
Minomic International Ltd, Suite 2, Ground Floor, 75 Talavera Rd, Macquarie Park, NSW 2113, Australia
Truong Q, Justiniano IO, Nocon AL, Soon JT, Wissmueller S, Campbell DH, Walsh BJ. Glypican-1 as a Biomarker for Prostate Cancer: Isolation and Characterization. J Cancer 2016; 7(8):1002-1009. doi:10.7150/jca.14645. Available from http://www.jcancer.org/v07p1002.htm
Prostate cancer is the most frequently diagnosed male visceral cancer and the second leading cause of cancer death in the United States. Standard tests such as prostate-specific antigen (PSA) measurement have poor specificity (33%) resulting in a high number of false positive reports. Consequently there is a need for new biomarkers to address this problem. The MIL-38 antibody was first described nearly thirty years ago, however, until now, the identification of the target antigen remained elusive. By a series of molecular techniques and mass spectrometry, the MIL-38 antigen was identified to be the highly glycosylated proteoglycan Glypican-1 (GPC-1). This protein is present in two forms; a membrane bound core protein of 55-60 kDa and secreted soluble forms of 40 kDa and 52 kDa. GPC-1 identification was confirmed by immuno-precipitation, western blots and ELISA. An ELISA platform is currently being developed to assess the levels of GPC-1 in normal, benign prostatic hyperplasia (BPH) and prostate cancer patients to determine whether secreted GPC-1 may represent a clinically relevant biomarker for prostate cancer diagnosis.
Keywords: Prostate Cancer, Glypican 1, Proteoglycan, Theranostic